Abstract 1440P
Background
Apatinib, a selective inhibitor of VEGFR2, showed a synergistic effect when combined with camrelizumab and chemotherapy in advanced esophageal squamous cell carcinoma (ESCC). We aim to assess the efficacy and safety of using the combination of camrelizumab with apatinib and chemotherapy as the neoadjuvant therapy for ESCC.
Methods
Patients with untreated, resectable (stage II or III) ESCC were enrolled. Each patient received two 21-day cycles of neoadjuvant treatment with intravenous camrelizumab, albumin-paclitaxel, carboplatin on day 1, and oral apatinib on days 1-14, followed by the third cycle without apatinib. The primary end point was pathological complete response (PCR). Secondary endpoints included safety, objective response rate (ORR) and disease control rate (DCR).
Results
Between February 2022 and November 2023, 70 eligible patients were enrolled. Three patients discontinued the treatment due to toxicity and 67 patients have completed the full three-cycle treatment. The ORR and DCR were 89.3% and 100%, respectively. 60 (85.7%) patients underwent surgery, and R0 resection was achieved in all cases. PCR was identified in 25 (41.6%) patients, and 5 (8.3%) patients had complete response of the primary tumor but residual disease in lymph nodes alone. Grade 3 or 4 trAEs included neutropenia (57.8%), leukopenia (55.2%), thrombocytopenia (28%), hepatitis (14.2%), febrile neutropenia (12.4%), hypertension (8.6%), and rash (4.2%). The median follow-up was 18.76 months and the 1-year DFS and OS rate was 90% and 95.7%. In prespecified exploratory biomarker analysis, PCR group exhibited elevated infiltrating cytotoxic T cells and effector memory T cells compared to the non-pCR group. Increased abundance of mature tertiary lymphoid structures was associated with PCR.
Conclusions
Neoadjuvant camrelizumab combined with apatinib and chemotherapy in patients with resectable ESCC achieved a high PCR rate (41.6%) and manageable trAEs. Larger cohorts are needed to examine whether this regimen is superior to that of camrelizumab combined with chemotherapy only regarding PCR and long-term survival.
Clinical trial identification
ChiCTR2100051763.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Institutional funding of First Affiliated Hospital of SUMS.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1456P - First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Presenter: Tianshu Liu
Session: Poster session 18
1457P - Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
Presenter: Guangyu Yao
Session: Poster session 18
1458P - Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer
Presenter: Shunyu Zhang
Session: Poster session 18
Resources:
Abstract
1459P - Long-term management and outcomes in gastroesophageal cancer in Norway
Presenter: Aleksander Kolstad
Session: Poster session 18
1460P - Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Presenter: Denice Kamp
Session: Poster session 18
1462P - A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Presenter: Bin Li
Session: Poster session 18
1463P - The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Presenter: Sebastiaan Siegerink
Session: Poster session 18
1464P - Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Presenter: Brian Housman
Session: Poster session 18
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18